Observes adults with Philadelphia-positive acute lymphoblastic leukemia receiving combined treatment
Follows adults with Philadelphia-positive acute lymphoblastic leukemia treated with combination therapy.
Plain-language title generated from the registry record
Registry title: EWALL-PH OBSERVARTORY 2022
Key facts
- Where
- Amiens, Angers, Bayonne, Bordeaux, Clamart, Clermont-Ferrand, Corbeil-Essonnes, Grenoble, La Réunion, Le Chesnay, Le Mans, Lille, Marseille, Nancy, Nice, Paris, Pierre-Bénite, Saint-Etienne, Strasbourg, and Toulouse, FranceSee the 23 sites
Where in France
- Groupe Hospitalier SUDAmiens, FranceNot yet recruiting
- CHU AngersAngers, FranceNot yet recruiting
- CH de la côte BasqueBayonne, FranceNot yet recruiting
- CHU BordeauxBordeaux, FranceTaking people
- Hôpital Militaire PercyClamart, FranceNot yet recruiting
- CHU Clermont-FerrandClermont-Ferrand, FranceTaking people
- Centre Hospitalier Sud FrancilienCorbeil-Essonnes, FranceTaking people
- CHU de GrenobleGrenoble, FranceNot yet recruiting
- CHU Sud RéunionLa Réunion, FranceNot yet recruiting
- CH VersaillesLe Chesnay, FranceTaking people
- CH Le MansLe Mans, FranceTaking people
- CHU de LilleLille, FranceNot yet recruiting
- Hôpital de la ConceptionMarseille, FranceNot yet recruiting
- Institut Paoli-CalmettesMarseille, FranceNot yet recruiting
- CHRU de NancyNancy, FranceNot yet recruiting
- Centre Antoine LacassagneNice, FranceNot yet recruiting
- Hôpital CochinParis, FranceNot yet recruiting
- Hôpital NeckerParis, FranceTaking people
- Hopital St-LouisParis, FranceTaking people
- CH de LyonPierre-Bénite, FranceNot yet recruiting
- CH St EtienneSaint-Etienne, FranceNot yet recruiting
- ICANSStrasbourg, FranceNot yet recruiting
- Hopital de PurpanToulouse, FranceNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Versailles Hospital
- Trial code
- NCT07684131
- Record updated
- 6 July 2026
- Original description
An observatory for patients aged 18 years and over with Philadelphia chromosome positive (Ph+ or BCR::ABL1) acute lymphoblastic leukemia (ALL) and treated with the combination of BCR::ABL1 inhibitors and chemotherapy and/or corticosteroids and/or a monoclonal antibody.Read full original descriptionShow less
AN OBSERVATORY FOR PATIENTS AGED 18 YEARS AND OVER WITH PHILADELPHIA CHROMOSOME POSITIVE (PH+ OR BCR::ABL1+) ACUTE LYMPHOBLASTIC LEUKEMIA (ALL) AND TREATED WITH THE COMBINATION OF BCR::ABL1 INHIBITORS AND CHEMOTHERAPY AND/OR CORTICOSTEROIDS AND/OR A MONOCLONAL ANTIBODY.
An observatory for patients aged 18 years and over with Philadelphia chromosome positive (Ph+ or BCR::ABL1) acute lymphoblastic leukemia (ALL) and treated with the combination of BCR::ABL1 inhibitors and chemotherapy and/or corticosteroids and/or a monoclonal antibody.
Inclusion: Male or female patients ≥ 18 years; Philadelphia chromosome or BCR::ABL1 positive acute lymphoblastic leukaemia; Treatment with the combination of BCR::ABL1 inhibitors and chemotherapy and/or corticotherapy and/or a monoclonal antibody.
Exclusion: Patients deceded and having previously refused data collection; Not included in a prospective clinical trial.